Abpro Bio Resolves Reverse Stock Split and Schedule Change: Aiming to Stabilize Stock Price via Per-Share Value Adjustment

Abpro Bio has decided on a reverse stock split merging 2 common shares into 1, reducing total outstanding shares from 32,575,748 to 16,287,874 and increasing par value from 500 won to 1,000 won.
The purpose of the merger is to stabilize the stock price and enhance corporate value by maintaining an appropriate number of listed shares; it does not constitute a capital reduction under commercial law as total equity remains unchanged.
The schedule has been partially adjusted: the general shareholders' meeting is set for June 12, 2026; new shares become effective on July 14; trading suspension period is from July 10 to July 29; and listing of new shares is expected on July 30.
Fractional shares of less than one share arising from the merger will be paid in cash based on the closing price on the first day of new share listing, and the plan may change depending on the shareholders' meeting resolution.
[AI Comprehensive Analysis]This is a simple reverse stock split with no direct impact on shareholder value, being neither particularly positive nor negative beyond price stabilization. However, potential undervaluation perception or reduced float may increase volatility, so investors should monitor short-term price movements.